Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.

Liang Xiao, Kye Il Joo, Matthew Lim, Pin Wang

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Many studies have demonstrated that prostate stem cell antigen (PSCA) is an attractive target for immunotherapy based on its overexpression in prostate tumor tissue, especially in some metastatic tissues. In this study, we evaluated dendritic cell (DC)-directed lentiviral vector (DCLV) encoding murine PSCA (DCLV-PSCA) as a novel tumor vaccine for prostate cancer in mouse models. We showed that DCLV-PSCA could preferentially deliver the PSCA antigen gene to DC-SIGN-expressing 293T cells and bone marrow-derived DCs (BMDCs). Direct immunization with the DCLV-PSCA in male C57BL/6 mice elicited robust PSCA-responsive CD8(+) and CD4(+) T cells in vivo. In a transgenic adenocarcinoma mouse prostate cell line (TRAMP-C1) synergetic tumor model, we further demonstrated that DCLV-PSCA-vaccinated mice could be protected from lethal tumor challenge in a prophylactic model, whereas slower tumor growth was observed in a therapeutic model. This DCLV-PSCA vaccine also showed efficacy in inhibiting tumor metastases using a PSCA-expressing B16-F10 model. Taken together, these data suggest that DCLV is a potent vaccine carrier for PSCA in delivering anti-prostate cancer immunity.

Original languageEnglish
JournalPLoS ONE
Volume7
Issue number11
DOIs
StatePublished - 2012

Fingerprint

Dive into the research topics of 'Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.'. Together they form a unique fingerprint.

Cite this